

provided by Covered Persons to customers, confidentiality issues should generally not arise. However, if the Board obtains any institution-specific information during an examination of a state member bank, such information may be protected under exemption (b)(8) of the Freedom of Information Act, which exempts from disclosure materials related to the examination of financial institutions (5 U.S.C. 552(b)(8)).

**Current actions:** On October 17, 2018, the Board published an initial notice in the **Federal Register** (83 FR 52452) requesting public comment for 60 days on the extension, without revision, of the Disclosure Requirements of Subpart H of Regulation H (Consumer Protections in Sales of Insurance). The comment period for this notice expired on December 17, 2018. The Board did not receive any comments.

Board of Governors of the Federal Reserve System, January 30, 2019.

**Michele Taylor Fennell,**

*Assistant Secretary of the Board.*

[FR Doc. 2019-00998 Filed 2-4-19; 8:45 am]

**BILLING CODE 6210-01-P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than February 19, 2019.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *F. Walter Riebenack, Evanston, Wyoming*, to retain individually, voting shares of UCSB Financial Corporation, and thereby indirectly retain shares of Uinta Bank, both of Mountain View, Wyoming, and for approval to become a member of the Riebenack/Gilbert

Control Group that owns voting shares of UCSB Financial Corporation. In addition, Keith L. Gilbert, Fort Wayne, Indiana, The Cyprian Fund, LLC of Mountain View, Wyoming, the estate of Barbara A. Gilbert, Fort Wayne, Indiana, Brian K. Gilbert and Andrea R. Gilbert, Naperville, Illinois, Fred L. Gilbert and Cynthia D. Gilbert, Singapore, James Gilbert and Christina Gilbert, Akron, Ohio, Terry Gilbert, Uniondale, Indiana, Andrea S. Worsham, Altamonte Springs, Florida, and Lindsay Worsham, Altamonte Springs, Florida, have applied for approval as members of the Riebenack/Gilbert Control Group to retain shares of UCSB Financial Corporation.

Board of Governors of the Federal Reserve System, January 30, 2019.

**Yao-Chin Chao,**

*Assistant Secretary of the Board.*

[FR Doc. 2019-00920 Filed 2-4-19; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[CDC-2018-0038; Docket Number NIOSH-312]

#### Continuing To Protect the Nanotechnology Workforce: NIOSH Nanotechnology Research Plan for 2018-2025

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of availability.

**SUMMARY:** NIOSH announces the availability of *Continuing to Protect the Nanotechnology Workforce: NIOSH Nanotechnology Research Plan for 2018-2015*.

**DATES:** The final document was published on January 25, 2019 on the CDC website.

**ADDRESSES:** The document may be obtained at the following link: <https://www.cdc.gov/niosh/docs/2019-116/>.

**FOR FURTHER INFORMATION CONTACT:** Charles L. Geraci ([CGeraci@cdc.gov](mailto:CGeraci@cdc.gov)), National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1090 Tusculum Ave., MS C-14, Cincinnati, OH 45226, phone (513) 533-8339 (not a toll free number).

**SUPPLEMENTARY INFORMATION:** On April 24, 2018, NIOSH published a request for public review in the **Federal Register** [83 FR 17824] of the draft version of the document *Continuing To Protect the Nanotechnology Workforce: NIOSH Nanotechnology Research Plan for 2018-2025*. All comments received were reviewed and addressed where appropriate.

**John J. Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2019-01039 Filed 2-4-19; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[CDC-2018-0024; Docket Number NIOSH-302]

#### Final National Occupational Research Agenda for Respiratory Health

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of availability.

**SUMMARY:** NIOSH announces the availability of the final *National Occupational Research Agenda for Respiratory Health*.

**DATES:** The final document was published on January 16, 2019 on the CDC website.

**ADDRESSES:** The document may be obtained at the following link: <https://www.cdc.gov/nora/councils/resp/agenda.html>.

**FOR FURTHER INFORMATION CONTACT:** Emily Novicki, M.A., M.P.H., ([NORACoordinator@cdc.gov](mailto:NORACoordinator@cdc.gov)), National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Mailstop E-20, 1600 Clifton Road NE, Atlanta, GA 30329, phone (404) 498-2581 (not a toll free number).

**SUPPLEMENTARY INFORMATION:** On March 15, 2018, NIOSH published a request for public review in the **Federal Register** [83 FR 11537 and 83 FR 19768] of the draft version of the *National Occupational Research Agenda for Respiratory*. All comments received

were reviewed and addressed where appropriate.

**John J. Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2019-01046 Filed 2-4-19; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket Number CDC-2019-0001, NIOSH-323]

#### Draft—National Occupational Research Agenda for Hearing Loss Prevention

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Request for comment.

**SUMMARY:** The National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention announces the availability of a draft NORA Agenda entitled *National Occupational Research Agenda for Hearing Loss Prevention* for public comment. To view the notice and related materials, visit <https://www.regulations.gov> and enter CDC-2019-0001 in the search field and click "Search."

#### Table of Contents

- Dates
- Addresses
- For Further Information Contact
- Supplementary Information
- Background

**DATES:** Electronic or written comments must be received by April 8, 2019.

**ADDRESSES:** You may submit comments, identified by CDC-2019-0001 and docket number NIOSH-323, by any of the following methods:

- *Federal eRulemaking Portal:* <https://www.regulations.gov> Follow the instructions for submitting comments.

- *Mail:* National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati, Ohio 45226-1998.

*Instructions:* All submissions received in response to this notice must include the agency name and docket number [CDC-2019-0001; NIOSH-323]. All relevant comments received will be posted without change to <https://www.regulations.gov>, including any

personal information provided. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226-1998.

#### FOR FURTHER INFORMATION CONTACT:

Emily Novicki (*NORACoordinator@cdc.gov*), National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Mailstop E-20, 1600 Clifton Road NE, Atlanta, GA 30329, phone (404) 498-2581 (not a toll free number).

**SUPPLEMENTARY INFORMATION:** The National Occupational Research Agenda (NORA) is a partnership program created to stimulate innovative research and improved workplace practices. The national agenda is developed and implemented through the NORA sector and cross-sector councils. Each council develops and maintains an agenda for its sector or cross-sector.

*Background:* The National Occupational Research Agenda for Hearing Loss Prevention is intended to identify the research, information, and actions most urgently needed to prevent occupational injuries. The National Occupational Research Agenda for Hearing Loss prevention provides a vehicle for stakeholders to describe the most relevant issues, gaps, and safety and health needs for the sector. Each NORA research agenda is meant to guide or promote high priority research efforts on a national level, conducted by various entities, including: Government, higher education, and the private sector.

This is the first Hearing Loss Prevention Agenda, developed for the third decade of NORA (2016-2026). It was developed considering new information about injuries and illnesses, the state of the science, and the probability that new information and approaches will make a difference. As the steward of the NORA process, NIOSH invites comments on the draft *National Occupational Research Agenda for Hearing Loss Prevention*. Comments expressing support or with specific recommendations to improve the Agenda are requested. A copy of the draft Agenda is available at <https://www.regulations.gov> (see Docket Number CDC-2019-0001).

**John J. Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2019-01045 Filed 2-4-19; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[CDC-2015-0021; Docket Number NIOSH-153-C]

#### Final Guidance Publications for Skin Notation Profiles

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of availability.

**SUMMARY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), announces the availability of the following 5 *Skin Notation Profiles* [DHHS (NIOSH) Publication No. 2019-117 to 2019-121]:

#### Substance(s)

Atrazine [CAS No. 1912-24-9]

Catechol [CAS No. 120-80-9]

Chlorinated Camphene [CAS No. 8001-35-2]

Pentachlorophenol (PCP) [CAS No. 87-86-5]

Sodium Fluoroacetate [CAS No. 62-74-8]

**DATES:** The final documents were published on January 11, 2019 on the CDC website.

**ADDRESSES:** The documents may be obtained at the following link: [https://www.cdc.gov/niosh/topics/skin/skin-notation\\_profiles.html](https://www.cdc.gov/niosh/topics/skin/skin-notation_profiles.html).

#### FOR FURTHER INFORMATION CONTACT:

Naomi Hudson, Dr.P.H, (*iuz8@cdc.gov*), Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS-C32, Cincinnati, OH 45226. Telephone: (513) 533-8388 (not a toll free number).

**SUPPLEMENTARY INFORMATION:** On May 1, 2015, NIOSH published a request for public review in the *Federal Register* [80 FR 24932] of 19 draft skin notation profiles. All comments received were reviewed and addressed where appropriate.

**John J. Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2019-01047 Filed 2-4-19; 8:45 am]

**BILLING CODE 4163-19-P**